Herceptin resistance database for understanding mechanism of resistance in breast cancer patients

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Ahmad, Sahil ^a   Gupta, Sudheer ^a   Kumar, Rahul ^a   Varshney, Grish C ^a   Raghava, Gajendra P S ^a  

^a INSTITUTE OF MICROBIAL TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TRASTUZUMAB;

BIOLOGY; BREAST NEOPLASMS; COPY NUMBER VARIATION; DRUG EFFECTS; DRUG RESISTANCE; FACTUAL DATABASE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MUTATION; PROCEDURES; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; DATABASES, FACTUAL; DNA COPY NUMBER VARIATIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; TRASTUZUMAB;

EID: 84897047467     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04483     Document Type: Article

References (49)

1. Rubin, I. & Yarden, Y. The basic biology of HER2. Ann. Oncol. 12 Suppl 1, S3-8 (2001).
2. Morrow, P. K. H., Zambrana, F. & Esteva, F. J. Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer. Breast Cancer Res. 11, 207 (2009).
3. Vu, T. & Claret, F. X. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front. Oncol. 2, 62 (2012).
4. Pohlmann, P. R., Mayer, I. A. & Mernaugh, R. Resistance to Trastuzumab in Breast Cancer. Clin. Cancer Res. 15, 7479-7491 (2009).
5. De, P., Hasmann, M. & Leyland-Jones, B. Molecular determinants of trastuzumab efficacy: What is their clinical relevance? Cancer Treat. Rev. 39, 925-34 (2013).
6. Duman, B. B., Sahin, B., Acikalin, A., Ergin, M. & Zorludemir, S. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer. J. BUON. 18, 44-50.
7. Kataoka, Y. et al.Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann. Oncol. 21, 255-62 (2010).
8. Park, B. H. & Davidson, N. E. PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance? Cancer Cell 12, 297-9 (2007).
9. Hicks, D. G. & Kulkarni, S. Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing. Arch. Pathol. Lab. Med. 132, 1008-15 (2008).
10. Zografos, G. C. & Roukos, D. H. Innovative biomarker development for personalized medicine in breast cancer care. Biomark. Med. 5, 73-8 (2011).
11. Kelloff, G. J. & Sigman, C. C. Cancer biomarkers: selecting the right drug for the right patient. Nat. Rev. Drug Discov. 11, 201-14 (2012).
12. Cayre, A., Mishellany, F., Lagarde, N. & Penault-Llorca, F. Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification. Breast Cancer Res. 9, R64 (2007).
13. Lourenço, H. M., Pereira, T. P., Fonseca, R. R. & Cardoso, P. M. HER2/neu detection by immunohistochemistry: optimization of in-house protocols. Appl. Immunohistochem. Mol. Morphol. 17, 151-7 (2009).
14. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-7 (2012).
15. Kumar, R. et al. CancerDR: cancer drug resistance database. Sci. Rep. 3, 1445 (2013).
16. Zaman, N. et al. Signaling network assessment of mutations and copy number variations predict breast cancer subtype-specific drug targets. Cell Rep. 5, 216-23 (2013).
17. Gajria, D. & Chandarlapaty, S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev. Anticancer Ther. 11, 263-75 (2011).
18. Nahta, R., Yu, D., Hung, M.-C., Hortobagyi, G. N. & Esteva, F. J. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat. Clin. Pract. Oncol. 3, 269-80 (2006).
19. Boutet, E., Lieberherr, D., Tognolli, M., Schneider, M. & Bairoch, A. UniProtKB/Swiss-Prot. Methods Mol. Biol. 406, 89-112 (2007).
20. Mitra, D. et al. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol. Cancer Ther. 8, 2152-62 (2009).
21. Nagy, P. et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res. 65, 473-82 (2005).
22. Huang, X. et al. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res. 70, 1204-14 (2010).
23. Wang, S. E. et al. Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol. Cell. Biol. 28, 5605-20 (2008).
24. Sassen, A. et al. Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer. Breast Cancer Res. 11, R50 (2009).
25. Lu, Y., Zi, X. & Pollak, M. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int. J. Cancer 108, 334-41 (2004).
26. Hevir, N., Tros?t, N., Debeljak, N. & Riz?ner, T. L. Expression of estrogen and progesterone receptors and estrogen metabolizing enzymes in different breast cancer cell lines. Chem. Biol. Interact. 191, 206-16 (2011).
27. Scaltriti, M. et al. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER21 breast cancer patients. Proc. Natl. Acad. Sci. U. S. A. 108, 3761-6 (2011).
28. The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells. Mol. Oncol. 7, 392-401 (2013).
29. Kang, S. H. et al. Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability. BMC Cancer 8, 286 (2008).
30. Vos, M. J., Kanon, B. & Kampinga, H. H. HSPB7 is a SC35 speckle resident small heat shock protein. Biochim. Biophys. Acta 1793, 1343-53 (2009).
31. Stepanova, L., Leng, X., Parker, S. B. & Harper, J. W. Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev. 10, 1491-502 (1996).
32. Carr, J. R., Park, H. J., Wang, Z., Kiefer, M. M. & Raychaudhuri, P. FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res. 70, 5054-63 (2010).
33. Liu, P. C. C. et al. Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol. Ther. 5, 657-64 (2006).
34. Gijsen, M. et al. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol. 8, e1000563 (2010).
35. Zhuang, G. et al. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res. 70, 299-308 (2010).
36. Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells. Cancer Lett. 313, 54-63 (2011).
37. Dokmanovic, M., Hirsch, D. S., Shen, Y. & Wu, W. J. Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer. Mol. Cancer Ther. 8, 1557-69 (2009).
38. Fessler, S. P., Wotkowicz, M. T., Mahanta, S. K. & Bamdad, C. MUC1 is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells. Breast Cancer Res. Treat. 118, 113-24 (2009).
39. Oliveras-Ferraros, C. et al. Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). Biochem. Biophys. Res. Commun. 397, 27-33 (2010).
40. Faratian, D. et al. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. Cancer Res. 69, 6713-20 (2009).
41. Shattuck, D. L., Miller, J. K., Carraway, K. L. & Sweeney, C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res. 68, 1471-7 (2008).
42. Gros, S. J. et al. Involvement of CXCR4 chemokine receptor inmetastastic HER2-positive esophageal cancer. PLoS One 7, e47287 (2012).
43. The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a metaanalysis. Curr. Med. Res. Opin. 29, 633-42 (2013).
44. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108-12 (2013).
45. Relationship between NF-kB, ER, PR, Her2/neu, Ki67, p53 expression in human breast cancer. Exp. Oncol. 34, 358-63 (2012).
46. Fasano, J. & Muggia, F. Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development. Ann. Oncol. 20, 609-14 (2009).
47. Su, G. H., Song, J. J., Repasky, E. A., Schutte, M. & Kern, S. E. Mutation rate of MAP2K4/MKK4 in breast carcinoma. Hum. Mutat. 19, 81 (2002).
48. Higgins, D. G., Thompson, J. D. & Gibson, T. J. Using CLUSTAL for multiple sequence alignments. Methods Enzymol. 266, 383-402 (1996).
49. Waterhouse, A. M., Procter, J. B., Martin, D. M. A., Clamp, M. & Barton, G. J. Jalview Version 2-a multiple sequence alignment editor and analysis workbench. Bioinformatics 25, 1189-91 (2009).